Neuroimmunology of status epilepticus
暂无分享,去创建一个
[1] E. Trinka,et al. Management of Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus , 2022, Continuum.
[2] D. Henshall,et al. Increased expression of the ATP‐gated P2X7 receptor reduces responsiveness to anti‐convulsants during status epilepticus in mice , 2021, British journal of pharmacology.
[3] S. Lattanzi,et al. Unraveling the enigma of new‐onset refractory status epilepticus: a systematic review of aetiologies , 2021, European journal of neurology.
[4] E. Aronica,et al. CXCL1-CXCR1/2 signaling is induced in human temporal lobe epilepsy and contributes to seizures in a murine model of acquired epilepsy , 2021, Neurobiology of Disease.
[5] T. Engel,et al. ATP and adenosine—Two players in the control of seizures and epilepsy development , 2021, Progress in Neurobiology.
[6] Q. Pittman,et al. Increased Excitatory Synaptic Transmission Associated with Adult Seizure Vulnerability Induced by Early-Life Inflammation in Mice , 2021, The Journal of Neuroscience.
[7] Takeshi Inoue,et al. Intrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome , 2021, Annals of clinical and translational neurology.
[8] R. Dingledine,et al. Peripheral Myeloid Cell EP2 Activation Contributes to the Deleterious Consequences of Status Epilepticus , 2020, The Journal of Neuroscience.
[9] R. Tulsawani,et al. Loss of Protection by Antiepileptic Drugs in Lipopolysaccharide-primed Pilocarpine-induced Status Epilepticus is Mediated via Inflammatory Signalling , 2020, Neuroscience.
[10] E. Elinav,et al. Inflammasome activation and regulation: toward a better understanding of complex mechanisms , 2020, Cell Discovery.
[11] F. Bertuzzi,et al. Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes , 2020, Diabetes Care.
[12] Linda K. Han,et al. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer , 2020, Breast Cancer Research.
[13] H. Butzkueven,et al. Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle? , 2019, Front. Immunol..
[14] K. Kothur,et al. Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infection‐related epilepsy syndrome and febrile status epilepticus , 2019, Epilepsia.
[15] A. Vezzani,et al. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy , 2019, Nature Reviews Neurology.
[16] S. Barbieri,et al. Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection–related epilepsy syndrome , 2019, Epilepsia open.
[17] P. Olejniczak,et al. Dexamethasone as Abortive Treatment for Refractory Seizures or Status Epilepticus in the Inpatient Setting , 2019, Journal of investigative medicine high impact case reports.
[18] R. Dingledine,et al. The COX-2/prostanoid signaling cascades in seizure disorders , 2018, Expert opinion on therapeutic targets.
[19] K. Chu,et al. Tocilizumab treatment for new onset refractory status epilepticus , 2018, Annals of neurology.
[20] R. Miles,et al. Microglial phenotypes in the human epileptic temporal lobe , 2018, Brain : a journal of neurology.
[21] L. Capelle,et al. Pannexin-1 channels contribute to seizure generation in human epileptic brain tissue and in a mouse model of epilepsy , 2018, Science Translational Medicine.
[22] T. Loddenkemper,et al. New‐onset refractory status epilepticus (NORSE) and febrile infection–related epilepsy syndrome (FIRES): State of the art and perspectives , 2018, Epilepsia.
[23] E. Aronica,et al. Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies , 2018, Neuropathology and applied neurobiology.
[24] A. Vezzani,et al. Inhibition of monoacylglycerol lipase terminates diazepam‐resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet , 2018, Epilepsia.
[25] A. Vezzani,et al. High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy , 2017, Brain, Behavior, and Immunity.
[26] Benjamin J. Whalley,et al. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection , 2017, Epilepsy & Behavior.
[27] Shumei S. Sun,et al. Plasma cytokines associated with febrile status epilepticus in children: A potential biomarker for acute hippocampal injury , 2017, Epilepsia.
[28] E. Wirrell,et al. Febrile infection‐related epilepsy syndrome treated with anakinra , 2016, Annals of neurology.
[29] R. Dingledine,et al. Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats , 2016, Neuropharmacology.
[30] K. Elisevich,et al. Brain region and epilepsy-associated differences in inflammatory mediator levels in medically refractory mesial temporal lobe epilepsy , 2016, Journal of Neuroinflammation.
[31] R. Ransohoff,et al. Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus , 2016, Proceedings of the National Academy of Sciences.
[32] Yu Wang,et al. Up-regulation of CXCL1 and CXCR2 contributes to remifentanil-induced hypernociception via modulating spinal NMDA receptor expression and phosphorylation in rats , 2016, Neuroscience Letters.
[33] Yi Wang,et al. Interleukin-1 receptor is a target for adjunctive control of diazepam-refractory status epilepticus in mice , 2016, Neuroscience.
[34] R. Wickström,et al. Cytokine and Chemokine Expression in CSF May Differentiate Viral and Autoimmune NMDAR Encephalitis in Children , 2016, Journal of child neurology.
[35] D. Henshall,et al. ATPergic signalling during seizures and epilepsy , 2016, Neuropharmacology.
[36] E. Aronica,et al. Immunity and Inflammation in Epilepsy. , 2016, Cold Spring Harbor perspectives in medicine.
[37] R. Dingledine,et al. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application , 2015, Expert review of neurotherapeutics.
[38] D. Henshall,et al. P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus , 2015, Epilepsy & Behavior.
[39] A. Zuckermann,et al. A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia–reperfusion injury and inflammation after on‐pump coronary artery bypass graft surgery , 2015, Clinical and experimental immunology.
[40] R. Dingledine,et al. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus , 2015, Neurobiology of Disease.
[41] Y. Takahashi,et al. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[42] M. Lythgoe,et al. Dexamethasone exacerbates cerebral edema and brain injury following lithium-pilocarpine induced status epilepticus , 2014, Neurobiology of Disease.
[43] Raymond Dingledine,et al. Cyclooxygenase‐2 in epilepsy , 2014, Epilepsia.
[44] J. Sandkühler,et al. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity , 2013, Nature Reviews Neuroscience.
[45] W. Löscher,et al. Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy , 2013, Neurobiology of Disease.
[46] D. Henshall,et al. P2X receptors as targets for the treatment of status epilepticus , 2013, Front. Cell. Neurosci..
[47] S. Cichon,et al. TLR4, ATF-3 and IL8 inflammation mediator expression correlates with seizure frequency in human epileptic brain tissue , 2013, Seizure.
[48] C. Mooney,et al. Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A‐438079 , 2013, Epilepsia.
[49] R. Dingledine,et al. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. , 2013, Trends in pharmacological sciences.
[50] H. Chugani,et al. Successful surgical treatment of an inflammatory lesion associated with new-onset refractory status epilepticus. , 2013, Neurosurgical focus.
[51] Q. Pittman,et al. Increased excitability and molecular changes in adult rats after a febrile seizure , 2013, Epilepsia.
[52] Masahito Hayashi,et al. An immunologic case study of acute encephalitis with refractory, repetitive partial seizures , 2012, Brain and Development.
[53] Q. Pittman,et al. Cytokines and brain excitability , 2012, Frontiers in Neuroendocrinology.
[54] Nan Zhang,et al. Elevated interleukin-8 enhances prefrontal synaptic transmission in mice with persistent inflammatory pain , 2012, Molecular pain.
[55] Annamaria Vezzani,et al. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products , 2011, Experimental Neurology.
[56] D. Nomura,et al. Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation , 2011, Science.
[57] Annamaria Vezzani,et al. Status epilepticus-induced pathologic plasticity in a rat model of focal cortical dysplasia. , 2011, Brain : a journal of neurology.
[58] T. Bártfai,et al. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures , 2011, Brain, Behavior, and Immunity.
[59] D. Janigro,et al. Efficacy of Anti-Inflammatory Therapy in a Model of Acute Seizures and in a Population of Pediatric Drug Resistant Epileptics , 2011, PloS one.
[60] K. Frei,et al. Brain Infiltration of Leukocytes Contributes to the Pathophysiology of Temporal Lobe Epilepsy , 2011, The Journal of Neuroscience.
[61] M. Lamkanfi,et al. HMGB1 release by inflammasomes , 2011, Virulence.
[62] R. Kohman,et al. The effects of age on lipopolysaccharide-induced cognitive deficits and interleukin-1β expression , 2011, Behavioural Brain Research.
[63] Quentin J. Pittman,et al. Contributions of peripheral inflammation to seizure susceptibility: Cytokines and brain excitability , 2010, Epilepsy Research.
[64] R. Sapolsky,et al. The Stressed CNS: When Glucocorticoids Aggravate Inflammation , 2009, Neuron.
[65] R. Raedt,et al. Effects of vagus nerve stimulation on pro- and anti-inflammatory cytokine induction in patients with refractory epilepsy , 2009, Journal of Neuroimmunology.
[66] Mark R Hutchinson,et al. The cortical innate immune response increases local neuronal excitability leading to seizures. , 2009, Brain : a journal of neurology.
[67] I. Najm,et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus , 2009, Neurobiology of Disease.
[68] Q. Pittman,et al. Neonatal inflammation produces selective behavioural deficits and alters N‐methyl‐d‐aspartate receptor subunit mRNA in the adult rat brain , 2008, The European journal of neuroscience.
[69] Eleonora Aronica,et al. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: Evidence from experimental models and human temporal lobe epilepsy , 2008, Neurobiology of Disease.
[70] M. Sayyah,et al. The bacterial endotoxin lipopolysaccharide enhances seizure susceptibility in mice: involvement of proinflammatory factors: nitric oxide and prostaglandins , 2003, Neuroscience.
[71] R. Sapolsky,et al. Novel glucocorticoid effects on acute inflammation in the CNS , 2003, Journal of neurochemistry.
[72] S. Garattini,et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus , 2000, The European journal of neuroscience.
[73] M. Walker,et al. Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. , 2019, Brain : a journal of neurology.